Engineered immune cells take on Hard-to-Treat pancreatic cancer

NCT ID NCT04146298

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation and a specific immune type (HLA-A*11:01). The goal is to see if the treatment is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Mutant KRAS G12V-specific TCR transduced autologous T cells
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer patients with the KRAS G12V mutation.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. There are risks of serious side effects from the chemotherapy and cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Changhai Hospital

    RECRUITING

    Shanghai, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.